Ä¢¹½ÊÓƵAPP

Monday, June 5, 2023

1:00 PM - 2:00 PM (Session Room 203)

• Michelle Werner, CEO-Partner of Ä¢¹½ÊÓƵAPP and CEO of Alltrna, joins Maya Martinez-Davis, President, U.S. at GSK; Meredith Manning, President of PharmaEssentia USA; and Erin Mistry, EVP and Chief Commercial Officer at CorMedix for a conversation moderated by Cynthia Isaac, Ph.D., Managing Director, Head of Corporate Communications Practice, Syneos Health

Tuesday, June 6, 2023

9:30 AM – 10:30 AM

• Geoffrey von Maltzahn, General Partner, Ä¢¹½ÊÓƵAPP joins Alaa Halawa, Executive Director & Co-Head of U.S. Ventures and Brian Goodman, General Partner, MPM Capital in a conversation moderated by John Carroll, Editor & Founder of Endpoints Ä¢¹½ÊÓƵAPP.

11:00 AM - 12:00 PM (Session Room 208)

• Lovisa Afzelius, Origination Partner, Ä¢¹½ÊÓƵAPP joins Raphael Townshend, PhD, Founder and Chief Executive Officer, Atomic AI; Zelanna Goldberg, Chief Medical Officer, Replicate Bioscience; and Angele Maki, PhD, SVP, Business Development, ReCode Therapeutics for a conversation moderated by Kouki Harasaki, Managing Partner, Bioluminescence Ventures.

11:00 AM - 12:00 PM

• Hamilton Bennett, Senior Director, Vaccine Access and Partnerships, Moderna joins Petro Terblanche, Afrigen Biologics and WHO mRNA Hub, Emma Wheatley, Director, Access and Private Partnerships, CEPI, Aminu Umar-Sadiq, Managing Director and CEO, Nigeria Sovereign Investment Authority, and Pierre Delsaux, Director-General, Health Emergency and Preparedness Response Authority, European Commission in a conversation moderated by Jeremy Knox, Head of Policy, Infectious Disease, Wellcome Trust.

3:00 PM - 3:45 PM (Session Room 205ABC)

• Noubar Afeyan, CEO and founder of Ä¢¹½ÊÓƵAPP sits down for a conversation with Stuart Cable, Vice Chairman, Global Chair of M&A for Goodwin

4:15 PM - 5:15 PM (Session Room 210A)

• Tuyen Ong, CEO of Ring Therapeutics and CEO-Partner at Ä¢¹½ÊÓƵAPP joins Michelle Mellion, MD, Senior Vice President, Head of Clinical Development, PepGen, and Howard Rutman, MD, MBA, Chief Medical Officer, Xalud Therapeutics, for a conversation moderated by Rowan Walrath, Life Sciences Reporter, Boston Business Journal

Thursday, June 8

9:00 AM - 10:00 AM (Session Room 206AB)

• , CSO of Tessera Therapeutics, joins Jeremy Duffield of Prime Medicine, Amy Simon of Beam Therapeutics, and Emile Nuwaysir of Ensoma, for a conversation moderated by Kouki Harasaki of Bioluminescence Ventures.

10:15 AM - 11:15 AM (Session Room 254A)

• Volker Herrmann, President and CEO of Sonata Therapeutics and CEO Partner of Ä¢¹½ÊÓƵAPP, joins a panel conversation with Dan Passeri, CEO, CUE BioPharma, and Ian Walters, CEO Portage Biotech, moderated by Angus Liu, Senior Writer, Fierce Pharma/Fierce Biotech

1:00 PM - 2:00 PM (Session Room 206AB)

• Luisa Salter-Cid, Chief Scientific Officer, Pioneering Medicines, Ä¢¹½ÊÓƵAPP, and , Chief Regulatory Officer at Tessera Therapeutics join Julianne Bruno, Senior Vice President, Programs and Portfolio at CRISPR Therapeutics for a conversation moderated by Cynthia Isaac, Managing Director, Head of Corporate Communications Practice, Syneos Health